Who
David R. Maraldo
EVP & Pres. MMD
Company insider
Files Form 4 as: EVP & Pres. MMD, Merck & Company.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $4.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 May 2026
- Last trade
- 5 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $465K6,311 at $73.73 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $812K6,311 at $128.72 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $846K9,709 at $87.10 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,311 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —9,709 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,686 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $1.2M9,709 at $128.72 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $228K2,686 at $84.71 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $346K2,686 at $128.72 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,311 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —9,709 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,686 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $465K6,311 at $73.73 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $812K6,311 at $128.72 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $846K9,709 at $87.10 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $1.2M9,709 at $128.72 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $228K2,686 at $84.71 | filing |
| 5 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $346K2,686 at $128.72 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,424 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —21,731 at $0.00 | filing |
News
Contrasting Merck & Co., Inc. (NYSE:MRK) and ABVC BioPharma (NASDAQ:ABVC)MRK · themarketsdaily.com · 21 Oct 2026Merck (MRK) Has New Cancer Treatments. Can They Outgrow the Keytruda Patent Cliff?MRK · insidermonkey.com · 20 Oct 2026Merck's 2.4% Dividend Yield: A Reliable Income Stream or a Risky Bet on Recovery?MRK · insidermonkey.com · 19 Oct 2026
0 headlines in the last 90 days name David R. Maraldo; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.